Candel Therapeutics 주식 (NASDAQ: CADL)

에 대한 최신 뉴스 Candel Therapeutics (NASDAQ:CADL) 주식

CANDEL THERAPEUTICS INC

Candel Therapeutics

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

3 Stocks With Strong Fundamentals Analysts Recommend For Long-Term Success

Equities

News

Markets

ADBE

CADL

TSLA

수요일(11일) 미국 증시는 최근의 인플레이션 보고서에 힘입어 낙관적인 분위기를 보였다. 나스닥 100 지수는 1.7% 급등하여 새로운 최고치를 기록했고, S&amp;P 500 지수는 0.8% 상승했다. 게임스탑, 어도비, 메타, 캔델 테라퓨틱스 및 테슬라

수요일 주목받은 주식: 게임스탑, 어도비, 메타, 캔델 테라퓨틱스 및 테슬라

Stocks Photo by Phongphan on Shutterstock

NVDA

PLTR

미국 주식 시장은 목요일에 하락하며, 다우존스 지수는 1.35% 하락한 38,596.98에 도달했다. NASDAQ와 S&amp;P 500도 각각 1.4% 하락한 16,049.08과 1.23% 하락한 5,147.21을 기록했다. 전체 시장의 하락에도 불구하고, 일부 종목은 소매 트레이더와 투자자들의 주목을 끌었다.



하루 내내 소매 트레이더와 투자자들의 관심을 끌은 주요 주식은 다음과

목요일의 주요 주식: 포드, 캔들 테라퓨틱스, 엔비디아, 팔란티어, 테슬라

Candel Therapeutics Inc

Cadeler AS

ROLR

High Roller Technologies Expects To Report Net Gaming Revenue Of About $798K And $1.15M In Finland For April 2025 And May 2025 Respectively

Canaccord Genuity analyst Luke Hannan maintains Dollarama (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DOL#TSX">DOL</a>) with a Hold and raises the price target from C$168 to C$178.

Price Target

Analyst Ratings

TSX:DOL

Canaccord Genuity Maintains Hold on Dollarama, Raises Price Target to C$178

Wedbush analyst Laura Chico reiterates Pharvaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHVS#NASDAQ">PHVS</a>) with a Outperform and maintains $27 price target.

Reiteration

PHVS

Wedbush Reiterates Outperform on Pharvaris, Maintains $27 Price Target

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is currently trading near the 596.57 level. For the bulls, we want to see buyers drive the price above 598.04. If strength continues above this area, the next key level to watch is 599.24. Holding 599.24 as support could open the door for buyers to push toward 600.51. If momentum remains on the buy side, the high bull target on the day sits at 601.22.&nbsp;
Should 596.57 give way during today's session, we will be watching for sellers to challenge 595.14. If bears continue to press lower, a move toward 593.73 would be likely. Further downside action could see 592.00 tested next. If the session sees heavy selling, the low bear target to monitor for SPY is 589.71.
Invesco QQQ Trust Series 1 (QQQ)
QQQ is currently hovering near the 528.44 level. Bulls want to see this level sustained with strength and buyers stepping in to reclaim 530.70 as firm support. If buyers maintain momentum, the next upside target is 532.52. Continued bullish follow-through may bring a move toward 533.70, with the high bull target for today set at 534.60.&nbsp;
If 528.44 weakens during regular trading hours, look for bears to gain control and test 527.03. A further decline could see price move toward 525.19. If the downtrend accelerates, expect sellers to probe 523.91. Breaking that level could pave the way for a move down to the low bear target of 522.57.
Apple Inc. (AAPL)
Apple is currently auctioning near the 202.29 level. For buyers, we are watching to see if they can lift the price to hold above 203.48. Continued bullish strength could push price action up to 204.33. If buyers remain active, a move toward 205.54 is possible, with the high bull target today at 206.55.&nbsp;
If Apple struggles to maintain 202.29 as support, we anticipate a potential test down toward 200.53. If selling continues to pick up, the next level to watch will be 199.51. Persistent downside momentum could bring 198.79 into play, with the low bear target for the session sitting at 198.22.
Microsoft Corp. (MSFT)
Microsoft is currently auctioning around the 463.27 level. Bulls are looking for sustained buying to push above this area and establish support at 464.70. Holding that level could lead to a move toward 466.44. If buying pressure remains strong, the high bull target for today is set at 467.65.&nbsp;
If 463.27 fails to hold as support, we anticipate a move down to test 462.07. Should the bears remain in control, look for further weakness toward 460.78. A break below that could drive price action down toward 459.18, with the low bear target for Microsoft resting at 457.25.
NVIDIA Corporation (NVDA)
NVIDIA is currently trading near our key level of 141.21. Bulls want to see a move higher toward 142.35 and a firm hold of that level as new support. If buying continues, the next target to the upside is 144.21. Should momentum stay positive, we could see NVIDIA approach 145.61, with the high bull target today at 147.06.&nbsp;
If 141.21 cannot hold as support, we expect sellers to press toward 140.28. Continued downside movement could bring the auction to test 139.42. If weakness persists, the next level to watch is 138.55. A strong move lower would have the bears targeting the session low at 137.94.
Alphabet Inc Class A (GOOGL)
Alphabet is currently trading around the 169.34 level. Bulls will look to build support here and push price higher toward 171.14. If the buying effort continues to drive the tape, the high bull target for today is 172.28.&nbsp;
Should 169.34 fail to act as support, sellers will likely look to move the price down to 167.04. If that level is broken, look for the bears to target 165.41. Continued downside could bring Alphabet to test the low bear target on the day at 163.79.
Meta Platforms Inc (META)
Meta is currently auctioning around the 689.09 level. Bulls want to see this level hold with strength, allowing buyers to push the price toward 692.10. If momentum builds, the next target for bulls is 695.62. A sustained rally could bring Meta toward the high bull target of 699.93.&nbsp;
If 689.09 loses support during today's session, sellers will likely press the auction lower to 683.97. Continued selling could test the next level at 679.79. If this level also breaks, the bears will aim for the low bear target today at 676.46.
Tesla Inc. (TSLA)
Tesla is currently trading near the 322.52 level. Buyers will want to push price action higher toward 327.59. If this level is secured, further upside could target 333.93. In the event of a broader market rally, Tesla could push toward 340.97, with the high bull target today set at 346.64.&nbsp;
If 322.52 breaks to the downside, we'll be watching for a test of 315.93. If selling pressure builds, expect sellers to press toward 312.42. A breakdown below this level could drive the auction lower toward the low bear target of 310.17.
Final Word:&nbsp;
Today's session brings several key economic reports to the forefront. At 8:30AM ET, we will see the release of Initial and Continuing Jobless Claims, April's Trade Balance, and the final Q1 readings for Non-Farm Productivity and Unit Labor Costs. Additionally, the Fed speaker calendar is active today with Kugler at 12PM ET, followed by Harker and Schmid at 1:30PM ET. Expect these events to generate periods of heightened market volatility, particularly as traders gauge the Fed's ongoing policy tone.&nbsp;
With a full slate of catalysts on deck and markets sitting at key technical levels, today's trading could see strong directional movement. Be prepared for volatility around the data releases and Fed commentary. Stay disciplined, follow your trade plan, and manage your risk carefully throughout the session. Good luck today!
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day—hours before it's published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

Trading Ideas

How To Trade SPY, Top Tech Stocks As Initial Jobless Claims Hit 247K Vs. 235K Expected

BCE's Bell Media Collaborates With Magna On Innovative Out-Of-Home Advertising Opportunities

Wedbush analyst Daniel Ives reiterates MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Outperform and maintains $300 price target.

Wedbush Reiterates Outperform on MongoDB, Maintains $300 Price Target

T-Mobile and SailGP are delivering the next era of live sports with real-time officiating, AI-guided camera angles and race marks that deliver data and broadcast footage — all connected by T-Mobile 5G at sea
SailGP, the global league that is redefining sailing, is getting a major tech upgrade from the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.t-mobile.com%2Fnews%2Fnetwork%2Ft-mobiles-network-global-speed-leader&amp;esheet=54266772&amp;newsitemid=20250605839152&amp;lan=en-US&amp;anchor=fastest+5G+network+in+the+nation&amp;index=1&amp;md5=c743428c03d225254093a0bd93907b76">fastest 5G network in the nation</a>. T-Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>), SailGP's exclusive U.S. 5G partner, is returning to the Mubadala New York Sail Grand Prix on Governors Island, June 7–8, with next-level 5G innovation. By deploying its 5G Advanced Network Solutions (5G ANS) — including hybrid and private networks along with network slicing — T-Mobile is powering smarter race operations, sharper camera angles and lightning-fast data delivery. The result: a more immersive and responsive experience for fans at home and real-time insights that help teams perform at the highest level on the water.

TMUS

SailGP Gets 5G Boost As T-Mobile Deploys 5G Advanced Network Solutions

Baiya International Group Inc. ("BIYA" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>), a human resource ("HR") technology company utilizing its cloud-based internet platform to provide one-stop crowdsourcing recruitment and SaaS-enabled HR solutions, today announced that Cathay Securities, Inc. and Revere Securities LLC, the underwriters of the Company's recent initial public offering of 2,500,000 shares of its ordinary shares, are partially waiving a lock-up restriction with respect to up to 2,950,000 shares of the Company's ordinary shares held by Datong International Group Ltd., Hesheng International Group Ltd., Hongfeng International Group Ltd., and Yilong International Group Ltd.
The partial waiver will take effect on June 5, 2025, and the shares may be sold on or after such date, subject to the terms of such waiver. The lock-up period will continue to apply with respect to all remaining shares subject to the lock-up agreements entered with the underwriters of the Company's initial public offering.

BIYA

Baiya International Group Announces Partial Lock-Up Waiver For 2.95M Shares

UBS analyst Michael Lasser maintains RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) with a Neutral and lowers the price target from $235 to $215.

UBS Maintains Neutral on RH, Lowers Price Target to $215

Xylo Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XYLO#NASDAQ">XYLO</a>) ("Xylo" or the "Company"), a technology-based company engaged in advanced innovative technologies, announced today that Viewbix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIX#NASDAQ">VBIX</a>), a global developer of ad-tech innovative technologies, has received approval for its shares of common stock to be listed on the Nasdaq Capital Market. Viewbix, in which Xylo holds an indirect stake through its 45.74% ownership in Gix Internet Ltd. ("Gix Internet"), which in turn owns 2,818,585 common shares representing 42.58% of Viewbix, expects its shares to commence trading on Nasdaq under the symbol "VBIX" on or about June 5, 2025, subject to continued compliance with Nasdaq exchange rules.

VBIX

XYLO

Xylo Technologies Says Viewbix Receives Approval For Its Shares To Be Listed On Nasdaq Capital Market

LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) shares are trading higher premarket on Thursday. The company inked an agreement and exclusive negotiations with AEQUITA regarding the sale of certain European olefins and polyolefins assets and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45787207/lyondellbasell-enters-into-an-agreement-and-exclusive-negotiations-with-aequita-for-the-sale-of-fo" rel="noreferrer noopener">operations for an undisclosed amount</a>.
The assets and operations to be acquired by AEQUITA encompass both integrated and stand-alone facilities within LyondellBasell's European olefins and polyolefins segment.
These assets include facilities located in Berre, France; Münchsmünster, Germany; Carrington, United Kingdom; and Tarragona, Spain.
Collectively, these facilities form a sizable and strategically positioned platform, located near a well-established customer base and offering strong access to essential infrastructure and logistics networks.
Notably, LyondellBasell and AEQUITA have entered into a put option agreement, under which AEQUITA is obligated to proceed with a pre-agreed purchase contract should LyondellBasell choose to exercise its option, following the completion of required consultations with employee representative bodies.
The transaction is anticipated to close in the first half of 2026, pending the conclusion of these consultation processes and customary closing conditions.
Peter Vanacker, LyondellBasell&#8217;s chief executive officer, said, &#8220;This contemplated transaction is a significant step in LYB&#8217;s transformation to Grow and Upgrade our Core.&#8221;
&#8220;Europe remains a core market for LYB and one we&nbsp;will continue to participate in following this transaction with more of a focus on value creation through establishing profitable leadership in circular and renewable solutions.&#8221;
In May, LyondellBasell disclosed a quarterly dividend of $1.37 per share, up 3 cents per share over the company&#8217;s first quarter 2025 dividend, payable on June 9, 2025, to shareholders of record date <a href="https://www.benzinga.com/pressreleases/25/05/g45583326/lyb-announces-increase-to-quarterly-dividend" target="_blank" rel="noreferrer noopener">as of June 2, 2025</a>.
In April, the company posted first-quarter revenue of $7.677 billion, topping estimates of $7.47 billion, while adjusted EPS came in at 33 cents, <a target="_blank" href="https://www.benzinga.com/25/04/45007588/lyondellbasell-stock-slips-despite-q1-revenue-beat-as-profit-margins-narrow-and-eps-misses-expectations" rel="noreferrer noopener">missing the consensus of 43 cents</a>.
Investors can gain exposure to the stock via Amplify ETF Trust Amplify Natural Resources Dividend Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NDIV#NYSE">NDIV</a>) and WBI Power Factor High Dividend ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBIY#NYSE">WBIY</a>).
Price Action: LYB shares are up 0.18% at $56.11&nbsp;premarket at the last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45406180/only-half-of-sp-500-stocks-joined-the-tariff-relief-rally-time-to-buy-the-laggards" target="_blank" rel="noreferrer noopener">Only Half Of S&amp;P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?</a></li>
</ul>
Photo: Shutterstock

NDIV

WBIY

LyondellBasell Moves To Sell European Assets As It Shifts Toward Circular, Renewable Growth

UBS analyst Trung Huynh maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Neutral and lowers the price target from $633 to $560.

REGN

UBS Maintains Neutral on Regeneron Pharmaceuticals, Lowers Price Target to $560

Mercurity Fintech Holding Inc. (the "Company," "we," "us," "our company," or "MFH") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>), a digital fintech group, today announced a strategic partnership with SBI Digital Markets (SBIDM), a subsidiary of SBI Digital Asset Holdings, the digital asset arm of Japan's leading conglomerate SBI Group. The underlying objective of this partnership is to accelerate the adoption of tokenized real-world assets (RWAs) and facilitate its global distribution through regulatory-compliant investment solutions.
The partnership between MFH and SBIDM establishes a framework for collaboration that will utilize their respective strengths to connect institutional capital with tokenized assets while ensuring full regulatory compliance across key markets.
Under the memorandum of understanding, MFH's subsidiary Chaince Securities, LLC will facilitate the distribution of SBIDM's tokenized asset offerings, with a focus on ensuring compliance with the rules and regulations of the Securities and Exchange Commission (SEC) and Financial Industry Regulatory Authority (FINRA). This collaboration will specifically target institutional investors, high-net-worth individuals, and accredited investors seeking sophisticated, compliant digital asset exposure. In parallel, SBIDM will provide tokenization technology and related infrastructure to MFH, supporting the Company's expansion of digital asset capabilities.

Mercurity Fintech Partners With SBI Digital Markets To Accelerate Adoption Of Tokenized Rwas And Facilitate Global Distribution Through Regulatory-Compliant Investment Solutions

UBS analyst Mauricio Serna maintains Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) with a Neutral and raises the price target from $54 to $56.

UBS Maintains Neutral on Oxford Industries, Raises Price Target to $56

<ul>
<li>TSLA</li>
<li>GLD</li>
<li>SLV</li>
<li>NVDA</li>
<li>GOOGL</li>
<li>BULL</li>
<li>RDDT</li>
<li>UNH</li>
<li>GOOG</li>
<li>CRWV</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

BULL

CRWV

GOOG

GOOGL

RDDT

Top 10 Trending Stocks On WallStreetBets As Of June 5, 2025 (Via Swaggy Stocks)

Inspira&#x2122; Technologies OXY B.H.N. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IINN#NASDAQ">IINN</a>) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA&#x2122; ART100 system (the "ART100 system"), in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations.
Inspira has ramped up strategic production in order to meet near-term delivery needs as Inspira expects these negotiations move toward finalization.&nbsp;The ART100 system, already implemented in clinical settings in the United States, is gaining traction as a reliable device for a critical care and emergency preparedness programs.

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Technologies Scales-Up Production Capabilities For FDA-Cleared INSPIRA ART100 System In Response To Expected Demand From European Governmental Authority

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

SILO

Silo Pharma Approves Purchase Of Up To $1M Bitcoin As Treasury Reserve Asset

Life Time Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>) ("Life Time" or the "Company") announced today the pricing of the previously announced underwritten secondary offering of 20,000,000 shares of the Company's common stock by certain selling stockholders, resulting in total gross proceeds of $590,000,000, before deducting underwriting discounts and commissions.
The offering is expected to close on June&nbsp;6, 2025, subject to the satisfaction of customary closing conditions. The selling stockholders will receive all of the proceeds from the proposed offering. The Company will not receive any of the proceeds from the sale of shares of the Company's common stock by the selling stockholders.
J.P. Morgan and BofA Securities are serving as the underwriters for the proposed offering. The underwriters propose to offer the shares to the public from time to time at a fixed price.

Offerings

Life Time Group Holdings Announces Pricing Of $590M Secondary Offering Of 20M Shares By Selling Stockholders, With No Proceeds To The Company

Real estate investor Grant Cardone used to be in the middle class, but setting ambitious goals helped him become wealthy and accumulate many assets. The high-profile entrepreneur knows what it means to live paycheck to paycheck and <a href="https://x.com/GrantCardone/status/1926109120110710889">doesn't endorse the lifestyle</a>.
This past experience is part of the reason why Cardone doesn't believe that the middle class should be an aspiration. Instead, he's worried that the middle-class lifestyle can offer too much comfort that doesn't address underlying financial challenges.
"Comfort makes more prisoners than all the prisons combined," Cardone stated.&nbsp;
Don't Miss:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
His comment doesn't just apply to the middle class. It's also for anyone who has put their big goals on hold and opted to stay where they are. These are some of the takeaways from Cardone's message.
<h2 class="wp-block-heading">Raise Your Financial Goals</h2>
If you are feeling comfortable, you should immediately raise your financial goals. Instead of contributing 10% of every paycheck to your portfolio, you should raise it by at least 1% per year. Setting this challenge will help you sharpen your finances and regularly monitor your budget. A renewed focus on financial objectives can turn your budget into an area of focus instead of a fleeting thought.
Raising your financial goals can also translate into a higher income. Bigger goals may inspire you to pick up a side hustle, ask for a raise, or switch jobs. Job hopping is one of the best ways to boost your income in the long run. You can grow your income much faster than 3% per year if you pursue this route.
Trending: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
Cardone set ambitious goals early in his life. He's had the goal of being a billionaire for many years, and that type of goal can result in massive action. You'll feel more alive and empowered if you're pursuing a goal like having a $1 billion net worth compared to only aiming for a $100,000 net worth.
<h2 class="wp-block-heading">Being Uncomfortable Is The Only Way To Grow</h2>
Growth occurs outside of the comfort zone. If you want to get muscles, you have to do regular workouts so your body can adapt, rest, and improve. You won't achieve your fitness goals by sitting on the couch all day, and the same logic applies to any goals in your life.
If you want to be a millionaire, you can't waste money on your credit card. Furthermore, you have to invest a higher percentage of every paycheck and commit to long-term goals. It's not easy to pursue big goals, but it's incredibly rewarding once you have achieved them.
Being comfortable feels easier at the moment, but people don't recognize the imprisonment of comfort until their negative habits have compounded over several months or years. It's easier not to do an extra side hustle, but you may have a smaller nest egg when you are in your 60s. Some people don't think about saving money and find themselves financially vulnerable when they reach their retirement years.
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
<h2 class="wp-block-heading">Change Your Environment</h2>
Getting out of your comfort zone may require changing your environment. You may have to move out of your hometown, make new friends, or join better online communities. Cardone left Louisiana for California to expand his horizons and get out of a familiar environment.&nbsp;
He moved from San Diego to Los Angeles when he felt like he was getting too comfortable. Then, he made another move from Los Angeles to Miami when he felt like he was getting too comfortable again.
Changing your environment will introduce you to new people, goals, and ideas. If you surround yourself with ambitious individuals, you may set more daring goals that require you to step out of your comfort zone more often. It's hard in the short run to step out of your comfort zone, but it's immensely rewarding in the long run. Staying out of your comfort zone beats dwelling in a prison without bars.&nbsp;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>
Image: Shutterstock

Personal Finance

Grant Cardone's Views On Comfort Explain Why He Sets Ambitious Goals For His Life And Finances: 'Comfort Makes More Prisoners Than All The Prisons Combined'

CXDO

Crexendo To Be Added To Russell 2000 Index And Russell 3000 Index Following 2025 Annual Reconstitution Of Russell Indexes

Health Care

Press Releases

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Candel Therapeutics to Present at Upcoming Investor Conferences

Earnings

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

DAWN

OSTX

YMAB

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Annexon

Astria Therapeutics

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Cardiff Oncology

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

Immutep Limited - American Depositary Shares

Immutep

Inozyme Pharma

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Neurogene

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Solid Biosciences

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Tevogen Bio Holdings

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

XOMA Royalty

HC Wainwright & Co.

Canaccord Genuity

Citigroup

B of A Securities

BMO Capital

Screenshot 2024-06-13 at 5.29.56 PM

Biotech

General

Candel Therapeutics&#39; (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments

Screenshot 2024-06-06 at 5.30.54 PM

Candel Therapeutics&#39; (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers

Screenshot 2024-05-31 at 5.22.29 PM

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

Screenshot 2024-04-04 at 9.54.11 PM

Chief Science Officer Talks Innovation In Cancer Research

Screenshot 2024-03-25 at 6.13.53 PM

The CEO Of This Innovative BioPharma Is Bringing Light To Cancer Research

Screenshot 2024-03-14 at 5.26.26 PM

Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors

Screenshot 2024-03-05 at 6.31.45 PM

CGON

CLDI

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-27 at 6.29.08 PM

Moving Fast: Candel&#39;s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer

수요일(11일) 미국 증시는 최근의 인플레이션 보고서에 힘입어 낙관적인 분위기를 보였다. 나스닥 100 지수는 1.7% 급등하여 <a href="https://www.benzinga.com/markets/equities/24/12/42452127/nasdaq-breaks-20000-milestone-as-tech-rally-rate-cut-hopes-fuel-market-optimism">새로운 최고치</a>를 기록했고, S&amp;P 500 지수는 0.8% 상승했다. 이러한 낙관적인 분위기는 다가오는 연방준비제도 이사회 회의에서 0.25%의 금리 인하가 있을 것이라는 기대에 힘입은 것이다. 기술 부문, 특히 "매그니피센트 세븐&#8221; 그룹의 초대형 주식들이 이러한 상승에 중요한 역할을 했다.
수요일에 개인 투자자와 트레이더들의 주목을 받은 종목은 다음과 같다.
1. 게임스탑 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>)
수요일 게임스탑의 주가는 7.58% 상승한 28.97달러에 마감했으며, 장중 최고가는 30.16달러, 최저가는 27.51달러였다. 52주 범위는 64.83달러~9.95달러다. 게임스탑의 <a href="https://www.benzinga.com/24/12/42447172/gamestop-shares-are-on-the-rise-wednesday-whats-going-on">3분기 재무 실적</a>에 따르면 순매출은 8억 6,030만 달러로, 컨센서스 추정치 $8억 8,770만 달러에 미치지 못했다. 매출은 모든 부문에서 감소했으며, 하드웨어 및 액세서리 부문은 전년도의 5억 7,940만 달러에서 감소한 4억 1,740만 달러를 기록했다.
2. 어도비 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>)
어도비 주가는 0.53% 소폭 상승하여 549.93달러에 마감했다. 이날 최고가는 552.3달러였고 최저가는 541.74달러였으며, 52주 범위는 638.25달러~433.98달러다. 4분기 매출이 56억 1천만 달러로 <a href="https://www.benzinga.com/news/earnings/24/12/42449013/adobe-q4-earnings-revenue-eps-beat-on-strong-demand-related-to-ai-shares-slide-following-soft-guidance">예상치인 55억 4천만 달러를 상회했다</a>. 조정 주당순이익은 4.81달러로 예상치인 4.66달러를 상회했다. 그럼에도 불구하고, 주가는 부진한 가이던스로 하락했다.
3. 메타 플랫폼스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)
메타 플랫폼스의 주가는 2.16% 상승하여 632.68달러로 마감했다. 주가는 장중 최고가인 638.4달러와 최저가인 621.53달러를 기록했으며, 52주 범위는 638.4달러~324.56달러였다. 페이스북, 인스타그램, 스레드, 왓츠앱에 영향을 미치는 <a href="https://www.benzinga.com/general/social-media/24/12/42446823/meta-platforms-suffers-major-outage-facebook-instagram-and-other-apps-down-for-thousands">주요 서비스 접속 장애</a> 사태를 겪었으며, 이로 인해 수천 명의 사용자들이 피해를 입었다. 이 문제는 다운디텍터닷컴이 보고했고, 메타는 인정했다.
4. 캔델 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>)
캔델 테라퓨틱스의 주가는 68.11% 급등하여 7.75달러를 기록했고, 최고가는 14.60달러, 최저가는 6.13달러였다. 52주 범위는 14.60달러~1달러다. 캔델은 전립선암에 대한 <a href="https://www.benzinga.com/24/12/42438029/candel-therapeutics-prostate-cancer-therapy-hits-primary-goal-in-late-stage-study-stock-surges-over-100">CAN-2409 바이러스 면역 요법</a>의 3단계 임상시험에서 성공적인 결과를 발표했으며, 1차 평가변수를 충족하고 무병 생존율이 크게 개선되었다고 밝혔다.
5. 테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라 주가는 5.93% 상승한 424.77달러에 마감했으며, 장중 최고가는 424.88달러, 최저가는 402.38달러였습니다. 52주 범위는 424.88달러~ 138.8달러다. 이 상승세에는 특히 모델 Y를 중심으로 한 <a href="https://www.benzinga.com/markets/equities/24/12/42438591/teslas-china-sales-recover-model-y-accounts-for-over-60-of-november-sales">중국에서의 강력한 성과</a>가 기여했다. 11월, 중국의 테슬라 소매 판매량은 73,490대에 달해 상당한 회복세를 보였다.
이미지 출처: Pixabay
벤징가의 주요 프리마켓 동향 및 뉴스로 <a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">하루의 거래를 준비하세요.</a>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

미국 주식 시장은 목요일에 하락하며, 다우존스 지수는 1.35% 하락한 38,596.98에 도달했다. 나스닥과 S&amp;P 500도 각각 1.4% 하락한 16,049.08과 1.23% 하락한 5,147.21을 기록했다. 전체 시장의 하락에도 불구하고, 일부 종목은 소매 트레이더와 투자자들의 주목을 끌었다.
하루 내내 소매 트레이더와 투자자들의 관심을 끌은 주요 주식은 다음과 같다:
포드 자동차(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>)는 3.22% 하락한 13.21달러에서 마감했다. 이 주식의 장중 최고가와 최저가는 각각 13.95달러와 13.17달러로, 52주간의 변동폭은 9.63달러에서 15.42달러다. 포드는 온타리오 주 오크빌 조립 단지에서 신형 3열 전기차 출시를 2025년에서 2027년으로 <a href="https://www.benzinga.com/markets/equities/24/04/38093618/ford-slows-down-electric-suv-production-amid-demand-concerns">연기한다고 발표했다</a>.
캔델 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>)은 280.95%의 상당한 폭의 급등을 기록한 6.4달러에 마감했다. 이 주식의 장중 최고가는 7.65달러로, 52주간의 변동폭은 0.66달러에서 7.65달러다. 이 회사는 현재 진행 중인 CAN-2409의 2상 임상시험에서 업데이트된 <a href="https://www.benzinga.com/general/biotech/24/04/38092867/after-brain-cancer-data-candel-therapeutics-shares-good-news-from-pancreatic-cancer-study">중간 생존 데이터를 발표했다</a>.
엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)는 3.44% 하락한 859.05달러에 마감했다. 이 주식의 장중 최고가와 최저가는 각각 906.34달러와 858.8달러, 52주간 범위는 262.2달러에서 974.00달러다. 엔비디아 주가는 <a href="https://www.benzinga.com/news/24/04/38083172/taiwan-earthquake-alarms-gene-munster-the-only-thing-that-can-slow-ai-in-the-near-term-is-impact-on" target="_blank" rel="noopener">대만의 강력한 지진</a>으로 인한 공급망 제약에 대한 우려로 인해 전일 하락한 후 목요일 개장 벨이 울리기 전에 <a href="https://www.benzinga.com/markets/equities/24/04/38087829/why-is-nvidia-stock-rising-premarket-after-a-pullback" target="_blank" rel="noopener">높게 거래</a>되었다.
팔란티어 테크놀로지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)은 0.97% 하락한 22.48달러에 마감했다. 이 주식의 장중 최고가와 최저가는 각각 24.1달러와 22.4달러, 52주간의 변동폭은 7.28달러에서 27.50달러다. Palantir 주가는 회사가 안전한 클라우드 및 AI 솔루션을 제공하기 위해 <a href="https://www.benzinga.com/markets/equities/24/04/38091895/whats-going-on-with-palantir-oracle-shares-after-they-inked-partnership">오라클과의 파트너십을 체결</a>한 후 목요일 상승세로 거래되었다.
테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)는 1.62% 상승한 171.11달러에 마감했다. 이 주식의 장중 최고가와 최저가는 각각 177.19달러와 168.01달러, 52주간의 변동폭은 152.37달러에서 299.29달러다. 최근의 하락에도 불구하고 한 분석가는 테슬라 주식의 <a href="https://www.benzinga.com/markets/equities/24/04/38083793/tesla-draws-79-upside-prediction-from-analyst-betting-on-impressive-full-self-driving">상당한 상승을 예상</a>했습니다.
Shutterstock의 Phongphan 씨 촬영
빠져나올 수 없는 <a href="Premarket Movers &amp; News">최고의 조기장세 동향과 뉴스와 함께</a> Benzinga의 도움을 받아 오늘의 거래를 준비하세요.
다음 기사 읽기: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38062216/bitcoin-ethereum-dogecoin-dip-amid-high-selling-pressure-analyst-says-king-crypto-will-not?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">비트코인, 이더리움, 도지코인의 고점 갱신은 단기 내 남아있지 않을 것</a>
<div style="font-family: 'Lato', sans-serif;">
<div>
<hr style="border: 0; height: 5px; background: #225aa9;" />
<div style="background-color: #f5f5f5; background-position: center; background-size: cover; justify-content: center;"></div>
<a class="ticker" style="color: #225aa9; text-decoration: none;" href="https://www.benzinga.com/ko/author/shivdeep-dhaliwal" rel="noopener">Shivdeep Dhaliwal</a>의 편집
<hr style="border: 0; height: 1px; background: #225aa9;" />
GPT-4 기반의 Benzinga Neuro 콘텐츠 생성 시스템은 네이티브 데이터, API 등 벤징가 생태계의 다양한 정보들을 활용하여 시기적절한 다양한 이야기를 제공합니다. <a style="color: #225aa9; text-decoration: none;" href="https://www.benzinga.com/author/benzinga-neuro" rel="noopener">더 알아보기</a>
<hr style="border: 0; height: 5px; background: #225aa9;" />
</div>
</div>

Comments

Candel Therapeutics

뉴스

에 대한 최신 뉴스 Candel Therapeutics (NASDAQ:CADL) 주식

목요일, 12월 12, 2024

금요일, 4월 05, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌